GSKIP Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 human lung adenocarcinoma epithelial line. This product features targeted disruption of the GSKIP gene, which encodes a scaffold protein that modulates GSK3?? activity and Wnt/??-catenin signaling. CRISPR/Cas9-mediated gene disruption was employed to inactivate GSKIP across a polyclonal cell population, providing a heterogeneous loss-of-function model suitable for robust functional studies.
The parental NCI-H1975 cell line originates from a non-small cell lung cancer (NSCLC) adenocarcinoma and is widely used to model lung tumor biology. These epithelial cells exhibit key oncogenic mutations and constitutive activation of Wnt/??-catenin and other mitogenic pathways, driving aggressive proliferation. NCI-H1975 cells are routinely used to investigate tumor cell signaling, drug resistance mechanisms, and anti-cancer compound efficacy, offering a clinically relevant platform for lung adenocarcinoma research.
GSKIP functions as an A-kinase anchoring protein that tethers PKA to the GSK3?¨CAxin?CAPC destruction complex, where it directly inhibits GSK3?? kinase activity. This inhibition blocks the phosphorylation of ??-catenin at Ser33/37/Thr41, thereby preventing its ubiquitination and proteasomal degradation. Stabilized ??-catenin enters the nucleus and activates TCF/LEF-mediated transcription of proliferative genes, including CCND1 (Cyclin D1) and MYC (c-Myc). GSKIP thus integrates cAMP/PKA and Wnt cues to govern cell growth and survival.
In the context of NCI-H1975 lung adenocarcinoma, loss of GSKIP is predicted to derepress GSK3??, enhancing ??-catenin degradation and attenuating Wnt target gene expression. This functional perturbation may impair clonogenic growth and reduce tumorigenic potential, providing insights into GSKIP??s role as an oncogenic facilitator in NSCLC. Consequently, this knockout model serves as a powerful tool to unravel the PKA?CWnt signaling axis and its contribution to lung cancer pathobiology, and to evaluate GSKIP as a potential therapeutic vulnerability.
Researchers can utilize these polyclonal knockout cells for mechanistic studies, including western blotting for ??-catenin and phospho-GSK3?? (Ser9), TOPFlash/FOPFlash dual-luciferase reporter assays to quantify Wnt transcriptional activity, and RT-qPCR to monitor changes in AXIN2, MYC, and CCND1 expression. Co-immunoprecipitation experiments can confirm the loss of GSKIP?CGSK3?? interaction. Additionally, the cells are suitable for immunofluorescence to assess ??-catenin subcellular localization, cell viability and proliferation assays (e.g., MTT, BrdU), and drug combination screens. For further technical details or custom services, please contact Ascent Research.
